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Abstract
Background: The aims of this study were to evaluate the effect of poloxamer 407 administration on atherogenic
serum lipoprotein fractions and subfractions associated with cholesterol, triglycerides and phospholipids, as well as
the onset of early atherosclerosis, in mice.
Methods: Mice were administered either sterile saline or poloxamer 407 (to induce a dose-controlled hyperlipidemia)
for 1 month and then sacrificed at 1, 4 and 10 days after the last dose of poloxamer 407. Systolic and diastolic blood
pressure, the activity of a cysteine protease (cathepsin B) in cardiac and liver tissue, and histological/morphological
examination of heart and liver specimens was performed for each group of mice at each time point. Lastly, small angle
X-ray scattering was utilized to analyze the lipoprotein fractions and subfractions associated with cholesterol,
triglycerides and phospholipids for both groups of mice at each time point. Statistical analysis was performed using
one-way, analysis-of-variance with post hoc analysis to determine significantly different mean values, while correlation
analysis employed the Spearman test.
Results: Poloxamer 407-treated mice revealed significant hyperlipidemia, moderately elevated blood pressure, general
lipidosis in liver cells, increased cysteine protease activity in heart tissue, and contractile-type changes in cardiomyocytes.
Similar to humans, the onset of atherosclerosis in poloxamer 407-treated mice was characterized by a steady increase in
serum low-density, intermediate-density and very-low-density lipoprotein fractions, as well as very-low-density
lipoprotein subfractions.
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Conclusions: We would propose that the sustained elevation of serum atherogenic lipoprotein fractions and subfractions
induced by the administration of poloxamer 407 to mice resulted in the morphological changes we observed in both
heart and liver cells, which are suggested to precede atherosclerosis, since this is a well-established mouse model of
atherosclerosis. Since most of the cellular, biochemical and physiological changes documented in the present study using
poloxamer 407-treated mice are related to the symptoms of early atherosclerosis in humans, it is suggested that the
poloxamer 407-induced mouse model of hyperlipidemia and atherosclerosis might prove beneficial as an experimental
animal model with which to evaluate the pathological features observed in early-stage atherosclerosis.
Keywords: Atherosclerosis, Cysteine protease (cathepsin B), Dyslipidemia, Lipoprotein fractions and subfractions, Liver
enzymes, Lysosomes, Macrophages, Poloxamer 407
Background
Early diagnosis and changes associated with atherosclerosis
are important to clinical medicine [1]. Different animal
models of hyperlipidemia and atherosclerosis (diet, genetic,
chemically-induced, etc.) have been developed [2, 3]. How-
ever, all animal models of hyperlipidemia and atheroscler-
osis have advantages and disadvantages. [4]. A particular
chemically-induced mouse model of hyperlipidemia and
atherosclerosis involves the chronic administration of a
block copolymer called poloxamer 407 (P-407) to mice of
either sex. This model produces significant dyslipidemia
(for approximately 4 days following a single dose) and sub-
sequent atherosclerosis accompanied by damage to heart
vessels [5]. The maximum serum total cholesterol and tri-
glyceride (TG) concentrations obtained after a single dose
of P-407 are dose-dependent. The P-407-mediated mouse
model of hyperlipidemia and atherosclerosis is a well-
established mouse model of atherogenesis, with aortic
atheroma formation commencing at about 1 monthnth
and attaining maximum lesion size and lesion numbers at
approximately 4 months following the initiation of P-407
treatment [6]. To maintain an atherogenic serum lipid
profile, P-407 must be dosed approximately every 3 days
for the 4-month period, although implantable, controlled-
release osmotic pumps represent an alternative to repeti-
tive intraperitoneal injections of P-407.
In the present study, we induced early atherosclerotic
lesion formation in mice by using repeated P-407 adminis-
tration at a relatively low dose for one month to produce a
sustained atherogenic serum lipid profile. One advantage
of the present study was the use of small-angle X-ray scat-
tering (SAXS) for the simultaneous evaluation of serum
lipoprotein-cholesterol (LP-C), lipoprotein-triglyceride
(LP-TG) and lipoprotein-phospholipids (LP-PL), which
allowed for the determination of the fractional and sub-
fractional composition of LP-C, LP-TG and LP-PL during
the onset of experimental atherosclerosis. The primary
motivation for lipoprotein fractionation and subsequent
analysis of the fractions into subfractions has been an
attempt to better treat patients at risk for coronary artery
disease resulting from atherosclerosis [7]. In brief, advanced
lipoprotein tests (those tests that separate the lipoprotein
fractions into subfractions) have been used in four basic
ways: 1) to enhance the accuracy of atherosclerosis risk pre-
diction, 2) to enhance the accuracy of outcome prediction,
3) to assist in treatment selection and dose adjustment, and
4) to counsel first-degree relatives of patients with
atherosclerosis [7]. A variety of analytical methods have
been utilized to achieve subfractionation of lipoproteins,
which include, but are not limited to, density gradient
ultracentrifugation, gradient gel electrophoresis, immuno-
affinity chromatography, ion mobility and 2-dimensional
gel electrophoresis [7]. However, standardization between
all of these techniques and the numerous fractions and
subfractions they produce is critically needed before their
widespread clinical application becomes routine practice
in cardiovascular medicine [7].
Therefore, the first aim of this study was to evaluate the
effect of prolonged (1 mo) P-407 treatment on alterations
in the serum concentrations of lipoprotein fractions and
subfractions associated with cholesterol, triglyceride and
phospholipid in mice, as well as to more precisely describe
the time-course over which the elevated serum fractions
and subfractions of LP-C, LP-TG and LP-PL returned to
baseline levels following discontinuation of P-407 treat-
ment. Our second aim was to determine any cellular,
biochemical, and/or pathophysiological changes in this
mouse model that are commonly associated with the
atherogenic cascade, e.g., changes in blood pressure, cell
structure/morphology, lipid movement and storage/se-
questration, blood glucose, the activity of serum enzymes
predictive of liver function (i.e., ALT and AST) and the ac-
tivity of a cysteine protease (cathepsin B) in cardiac and
hepatic tissue. Our overarching goal was to more fully
characterize the pathological changes associated with
early-stage atherosclerosis in the P-407-induced mouse
model of hyperlipidemia and atherosclerosis.
This article reports the progressive increase in serum
low-density, intermediate-density and very-low-density
lipoprotein fractions, as well as very-low-density lipoprotein
subfractions in P-407-treated mice, which is commonly ob-
served in human patients with developing coronary artery
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atherosclerotic heart disease. In addition, we report in
this article that P-407-treated mice, in addition to
manifesting hyperlipidemia, exhibited moderately elevated
blood pressure, general lipidosis in liver cells, increased
cathepsin B activity in cardiac tissue, and contractile-type
morphological changes in cardiomyocytes; all changes
frequently associated with the development of early
atherosclerosis in humans.
Results
Effect of repeated P-407 administration on blood pressure
in mice
Following 1 month of P-407 treatment, there was a slight
upward trend in both the systolic and diastolic blood
pressure in mice when compared to controls treated with
saline (Fig. 1). Mean values for both the systolic and
diastolic blood pressure followed the rank order; P-407-
treated mice > saline-treated controls > non-treated con-
trols and demonstrated that even the treatment protocol
(2 injections per week) results in an upward trend in blood
pressure as demonstrated by an elevated systolic and
diastolic blood pressure in saline-treated controls versus
non-treated controls (Fig. 1).
Effect of repeated P-407 administration on serum protein,
glucose, ALT and AST
Both serum total protein (p < 0.01) and ALT activity
(p < 0.05) were significantly elevated, relative to controls,
24 h following cessation of P-407 treatment for 1 month
(Table 1). The serum glucose concentration was sig-
nificantly (p < 0.05) reduced at 4 days after the last
dose of P-407 when compared to controls (Table 1).
There was a positive correlation between total serum
protein and total cholesterol (Spearman correlation
coefficient = 0.722, t = 2.95, p < 0.02) and total serum
protein and TG (Spearman correlation coefficient =
0.687, t = 2.67, p < 0.03). Additionally, there was a
positive correlation between serum non-HDL choles-
terol and ALT activity (Spearman correlation coeffi-
cient = 0.783, t = 3.55, p < 0.01), non-HDL-cholesterol
and AST activity (Spearman correlation coefficient =
0.764, t = 3.35, p < 0.01), and total serum cholesterol
and glucose (Spearman correlation coefficient = 0.692.
t = 2.71, p < 0.05).
Serum LP-C, LP-TG and LP-PL concentrations; their fractions
and subfractions
Figures 2a, b and c show all of the lipoprotein fractions
and subfractions associated with cholesterol (Fig. 2a),
TG (Fig. 2b) and phospholipids (Fig. 2c) determined at
24 h, 4 d and 10 d following the last dose of P-407,
which was administered to mice for 1 month. Some
overall general trends are noteworthy. To begin, if one
considers the total serum LP-C, LP-TG and LP-PL (i.e.,
the first group of 4 bars in Figs. 2a, b and c, respect-
ively), each lipid was significantly (p < 0.001) elevated
over control values at 24 h. By 4 days post-treatment, all
three lipids had decreased to serum concentrations that
were approximately equal to control values. As explained
in the Methods section, the Kch for P-407-treated mice
(24 after stopping P-407 administration) was 2.3 compared
to 0.37 for control mice, which is a greater than 6-fold
increase in the value of Kch for P-407-treated mice and
provides, based on serum concentrations of lipoproteins
alone, additional validation as to the degree of atherogeni-
city and propensity for atherosclerosis in the P-407 model.
As it pertains to only non-HDL lipoprotein fractions and
subfractions associated with cholesterol (Fig. 2a), VLDL,
LDL and IDL remain significantly elevated 24 h after P-
407 treatment is stopped when compared to controls,
while HDL lipoprotein fractions and subfractions appeared
to return to normal levels in a more gradual fashion.
In contrast, lipoprotein fractions and subfractions as-
sociated with triglyceride (Fig. 2b), show that, in general,
the VLDL fraction and subfractions contained more TG.
This would seem to support our previous findings,
which have demonstrated that the elevation in serum
TG is more pronounced than the rise in serum total
cholesterol in P-407-treated mice and that most of the
TG is associated with the VLDL fraction [6]. Addition-
ally, the LDL, IDL and HDL lipoprotein fractions and
subfractions associated with TG were significantly
greater than corresponding mean values for controls
24 h after the last dose of P-407 (Fig. 2b).
Finally, there was a significant elevation in the HDL
lipoprotein fraction (p < 0.01), and subfractions (p < 0.05)
Fig. 1 Systolic (□) and diastolic (■) blood pressure in mice following
prolonged (1 mo) administration of poloxamer 407. Blood pressure
measurements were obtained 24 h following discontinuation of P-407
treatment and 8 h prior to sacrifice. Filled and open square symbols
represent the median values, whereas the upper and lower point of
the vertical lines (“whiskers”) represent the maximum and minimum
blood pressure reading, respectively. Horizontal hash marks (lines)
through the vertical lines represent the values of the 1st-quartile, or
25th percentile (lower) and 3rd-quartile, or 75th percentile (upper)
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associated with phospholipid (Fig. 2c) 24 h after the last
dose of P-407 relative to controls. When compared to
corresponding mean values for controls, it should also
be noted that there was a significant increase in the
LDL lipoprotein fraction (p < 0.001) and subfraction
(LDL1–3) (p < 0.001), as well as the IDL lipoprotein
fraction (p < 0.05), associated with phospholipid 24 h
after stopping P-407 administration (Fig. 2c).
Degree of lysosomal membrane permeability
Liver lysosomes examined 24 h after the last dose of
P-407 revealed a significant (p < 0.05) increase in the
free activity of β-galactosidase (Fig. 3a), as well as a
significant (p < 0.01) increase in their susceptibility to
hypoosmotic treatment in vitro when 0.125 M sucrose
was used (Fig. 3b).
Cathepsin B activity in liver and heart tissue
The specific activity of cathepsin B in liver tissue in-
creased modestly 24 h after stopping P-407 treatment
for 1 month, although it did not reach statistical signifi-
cance when compared to control (data not shown). In
contrast, the specific activity of cathepsin B in heart
tissue remained significantly (p < 0.01) elevated relative
to control for as long as 24 h after the last dose of P-407
(Fig. 4); however, the enzyme activity began to normalize
and returned to normal (control) values by day 4 follow-
ing discontinuation of P-407 treatment (Fig. 4).
Morphological evaluation of liver and heart cells
Light microscopy of liver cells
Liver cells obtained from mice 24 h after discontinuation
of P-407 treatment revealed discomplexation of liver cells,
signs of local intrahepatic cholestasis, (Fig. 5b and c) and
venous stasis (Fig. 5c) compared to controls (Fig. 5a). An
increase in the size of the sinusoids was noted 4 days after
discontinuation of P-407 treatment (Fig. 5b). Hepatocytes
were increased in size and exhibited a cytoplasm that ap-
peared “foamy” (Fig. 5b and c). Numerous macrophages,
which also appeared to contain a “foamy” substance, were
observed in enlarged sinusoids and in periportal zones.
This was particularly evident by day 4 following discon-
tinuation of P-407 treatment (Fig. 5b). Similar changes
were also noted 10 days after stopping P-407 treatment
(Fig. 5c). Additionally, in some cells, vesicular lipid dys-
trophy was noted. This is particularly evident with Sudan
III and hematoxylin stain at both 24 h and 4 days follow-
ing the discontinuation of P-407 treatment (Fig. 6d and f)
when compared to control (Fig. 6b). Finally, hepatocytes
appeared to have been mildly infiltrated with lymphocytes,
which seemed to lessen 10 days following cessation of
P-407 treatment. In summary, liver injury in P-407-
treated mice was characterized by lipid storage in liver
cells (especially in macrophages), discomplexation of liver
cells and increased cholestasis (Figs. 5b, c and 6c–f ).
Light microscopy of cardiomyocytes
When compared to cardiomyocytes isolated from controls
(Fig. 5d), changes observed in P-407-treated mice con-
sisted primarily of damage to contractile-type cardio-
myocytes (Fig. 5e), which is typical for lipidosis
(Figs. 5e and f). There was swelling of the muscle layer
inside of membrane vessels, together with adherence of
fibrin and erythrocytes to the luminal wall of vessels
(Fig. 5e). Xanthoma cells had infiltrated the perivascular
zones. Twenty-four hours after the last dose of P-407,
xanthoma cells had also infiltrated the matrix area,
and, by day 4, these same type of cells were observed
in the endocardial space.
Discussion
Diagnosis of early atherosclerosis is important for
prophylactic treatment strategies to combat this disease
[8, 9]. The use of animal models to provide new
approaches for improving the diagnosis and treatment of
cardiovascular diseases is extremely important to cardio-
vascular medicine [10, 11]. The advantage of the dose-
dependent, pharmacologically-induced mouse model of
hyperlipidemia and atherosclerosis used in the present
work is that it reliably recapitulates the phenotypic
signatures associated with the pathogenesis of human
atherosclerosis (hyperlipidemia, atheroma formation, car-
diac muscle and vessel injury, etc.) [6]. Moreover, high
levels of circulating LP-cholesterol in the P-407 model par-
tially reproduces familial hypercholesterolemia and familial
combined hyperlipidemia (inherited disorders associated
Table 1 Time-dependent return of select biochemical parameters to normal concentrations following 1 month of poloxamer
407 administration to mice
Analyte Control P-4071 (24 h) P-4071 (4 days) P-4071 (10 days)
Total protein (g/l) 64.8 ± 11.1 **120 ± 4.7 61.2 ± 7.4 63.8 ± 0.9
Glucose (mg/dl) 79.5 ± 5.8 82.9 ± 5.0 *54.0 ± 2.2 66.7 ± 3.8
ALT (U/l) 37.8 ± 4.5 *50.1 ± 4.7 28.5 ± 1.9 29.1 ± 1.1
AST (U/l) 144 ± 11.3 146 ± 14.3 152 ± 9.0 165 ± 17.4
1Times indicate the time period following the discontinuation of P-407 administration for 1 month
*p < 0.05
**p < 0.01 vs. control
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Fig. 2 Serum lipoprotein fractions and subfractions associated with cholesterol (LP-C) (a) triglycerides (LP-TG) (b), and phospholipids (LP-PL) (c) in
mice following prolonged (1 mo) administration of poloxamer 407. Dark-grey, black and light-grey bars (bars 2, 3 and 4 in each group of 4 bars)
indicate the concentration of either LP-C, LP-TG or LP-PL at 1, 4 and 10 days after stopping P-407 administration, respectively, whereas the open
or unfilled bar (bar 1 in each group of 4 bars) indicates the concentration of either LP-C, LP-TG or LP-PL in saline-treated (control) mice. a, b and
c above bars indicate p < 0.001, p < 0.01, and p < 0.05, respectively, vs. control
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with increased circulating LDL-cholesterol and severe ath-
erosclerosis) in humans with poor prognosis and treatment
[12]. Thus, this model has proven beneficial for the study
of various stages involved with hyperlipidemia-induced
atherosclerotic lesion formation and has been utilized to
effectively screen the potency and efficacy of several classes
of anti-hyperlipidemic drugs [13, 14], as well as demon-
strate the effectiveness of atorvastatin to cause regression
of established atherosclerotic lesions [13].
The present work demonstrated that the atherogenic
serum lipid profile induced with P-407 treatment in mice
is reversible once P-407 administration is discontinued.
One of the main findings in our study was that repetitive
dosing of P-407 in mice induced a hyperlipidemic state
that more closely resembles hyperlipidemia observed in
the early stages of atherosclerosis in humans, with simul-
taneous development of liver lipidosis and early signs of
heart injury. Importantly, because it is known that the
total serum cholesterol concentration alone does not
accurately predict the risk of cardiovascular disease in
many patients [15], we simultaneously evaluated all of the
fractions and subfractions of LP-C, LP-TG and LP-PL by
employing SAXS analysis [16, 17].
Using SAXS, one of our goals in the present investiga-
tion was to quantify the serum concentrations of lipopro-
tein fractions and subfractions associated with cholesterol,
triglyceride and phospholipid in P-407 treated mice rela-
tive to controls. These findings will now be discussed in
relation to the P-407-induced mouse model of atherogen-
esis. In each and every case (with the exception of the
VLDL1–2 subfraction associated with cholesterol), the
atherogenic (i.e., VLDL1–2, VLDL3–5, IDL and LDL1–3)
and antiatherogenic (i.e., HDL2 and HDL3) lipoprotein
fractions and subfractions associated with cholesterol, TG
and PL in mice were significantly greater 24 h after
discontinuing P-407 administration when compared to
controls. Irrespective of the serum concentrations of all
lipoprotein fractions and subfractions in P-407-treated
mice relative to control mice, it is extremely important to
emphasize that despite the presence of antiatherogenic
HDL3, and especially HDL2, the capacity for the athero-
genic lipoprotein fractions and subfractions to induce the
formation of aortic atherosclerotic lesions in P-407-
treated mice is not completely inhibited by HLD2 and
HDL3, since this is a well-established mouse model of
hyperlipidemia and atherogenesis [6, 13, 18, 19]. Addition-
ally, as it relates to the atherogenicity of lipoprotein
fractions and subfractions, the intensity of the atherogenic
response in P-407-treated mice is greatly enhanced by the
enormous increase in the LDL fraction and subfractions,
which undergo spontaneous lipid peroxidation to form
oxidized-LDL (ox-LDL) in vivo [20]; a highly-atherogenic
Fig. 3 The effect of prolonged (1 mo) administration of P-407 in mice
on liver lysosomal membrane permeability as suggested by (a) the re-
lease of β-galactosidase, which is expressed as the free activity of
β-galactosidase as a percent of the total activity, and (b) hypoosmotically-
induced membrane rupture, which is expressed as the increment of
free activity of β-galactosidase. * and ** indicates p < 0.05 and p < 0.01,
respectively, vs. control
Fig. 4 Cathepsin B activity in heart tissue after prolonged poloxamer
407 administration in mice. Data points at 1, 4 and 10 days for both
P-407-treated (dashed line with open circles) and control (solid line
with filled circles) mice represent the elapsed time period after stopping
P-407 dosing for 1 month. *indicates p < 0.01 vs. control
Korolenko et al. Lipids in Health and Disease  (2016) 15:16 Page 6 of 13
lipoprotein particle capable of easily entering the arterial
intima through transendothelial migration [21].
It was interesting to note in our work that serum non-
HDL-cholesterol exhibited a strong association with
both serum ALT and AST activity (Spearman correlation
coefficients were approximately equal to 0.8), because
Jiang et al. has recently shown a U-shaped relationship
between serum non-HDL-cholesterol and elevated trans-
aminases (both ALT and AST) in humans [22]. Jiang et
al. suggest that there may be a strong association
between lipoprotein metabolism and liver diseases/injury
when serum non-HDL-cholesterol is either extremely
low, or extremely high. These authors determined that
the same U-shaped relationship also existed for a more
narrow portion or component of the total non-HDL-
cholesterol; namely, between just serum LDL-C alone
and serum transaminases [22]. While an association
does not prove causality, nevertheless, the extremely
high non-HDL-cholesterol fractions and subfractions
seen with P-407-treated mice may be associated with the
elevations in serum ALT and AST we observed in the
present study.
Jiang et al. suggest that disorders in lipoprotein metabol-
ism may potentially lead to hepatic injury, whereas chronic
liver disease may also interfere or impair lipoprotein pro-
duction. Interestingly, we have previously demonstrated
that the activity of key enzymes and, more specifically,
lipases involved with lipid metabolism (e.g., hepatic lipase,
lipoprotein lipase, endothelial lipase and pancreatic lipase)
are either partially, or fully, inactivated in vivo in P-407-
treated mice [23, 24]. This would clearly represent a dis-
order, or disturbance, in lipid and lipoprotein metabolism,
Fig. 5 Light microscopic findings of liver (a, b, c) and heart (d, e, f) of mice following prolonged (1 mo) administration of poloxamer 407. All specimens
were stained with hematoxylin and eosin at the magnification indicated. а Liver of control mice, 400 X. b Liver of mice 4 days after discontinuation of
P-407 administration. Hepatocytes and macrophages exhibited ‘foamy’ cytoplasm, 400 X. с Liver of mice 10 days after discontinuation of
P-407 administration. Increased number of ‘foamy’ macrophages are visible, which appear to be localized in sinusoids and in the periportal zone, 400 X. d
Myocardium of control mice, 200 X. e Myocardium of mice 24 h after discontinuation of P-407 administration. Swollen vessel walls of the muscle-elastic
type are visible, together with localized changes of contracture-type cardiomyocytes shown with arrows, 400 X. f Myocardium of mice
24 h after discontinuation P-407 administration. Perivascular edema in the walls of blood vessel in interstitial tissue with groups of cells
overloaded with lipids (arrow), 400 X
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which, according to Jiang et al., could potentially
cause hepatic injury and hence, contribute to an
elevation in ALT and AST activity in the serum of P-407-
treated mice. When taken together with the morpho-
logical changes in specific cells of liver tissue (i.e.,
liver injury resulting from elevated lipid influx and
sequestration, since P-407 itself is not hepatotoxic),
which we have documented in P-407-treated mice, it may
be that hepatic lipoprotein production is potentially
altered/perturbed due to these pathophysiological
changes as suggested by Jiang et al. This finding would
lend support to their hypothesis of a bidirectional
relationship between lipoprotein metabolism and liver
injury/disease [22].
Early, but subtle, changes in cardiomyocytes resulting
from prolonged administration of P-407 in mice were
documented with light microscopy in the present
study. Changes to contractile-type cardiomyocytes in
coronary vessels were observed, which usually pre-
cedes atheroma formation. In fact, we have previously
reported these same changes to contractile-type cardi-
omyocytes and similar, but more pronounced, coron-
ary vessel injury following extended (4 mo) P-407
treatment in mice [5].
Fig. 6 Lipid staining in liver of mice after 1 month of P-407 administration. H&E = hematoxylin and eosin staining, while S&H= Sudan III and hematoxylin
staining. Magnification is represented by linear distance according to the scale on each histology slide (a) through (f). a Liver of control mice, H&E. b Liver
of control mice, S&H. c Liver of mice 24 h after discontinuation of P-407 administration for 1 month. Mild vacuolar
dystrophy of hepatocytes, together with necrosis of some hepatocytes, H&E. d Liver of mice 24 h after discontinuation of P-407 administration for 1 month.
All hepatocytes are filled with small and medium-sized lipid droplets, thus displaying significant lipid dystrophy, S&H. e Liver of mice at 4 days after
discontinuation of P-407 administration for 1 month. Hepatocytes are significantly enlarged and homogenously stained. There is diffuse leukocyte
infiltration visible. The portion of hepatocytes demonstrating necrosis appear to have incorporated erythrocytes (arrows), H&E. f Liver of mice 4 days after
discontinuation of P-407 administration for 1 month. All hepatocytes are filled with small lipid droplets, thus displaying significant lipid dystrophy, S&H
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The potential link between the inflammatory effects of
lipemia and the induction of macrophage foam cell
formation by triacylglycerol-rich lipoproteins has been
shown by others [25, 26]. When inflow and esterification
of cholesterol increase and/or its outflow decrease, mac-
rophages are ultimately transformed into lipid-laden
foam cells; the prototypical cells formed in atheroscler-
otic plaque [27]. In the present investigation using light
microscopy, we observed numerous liver macrophages
containing lipid material (xanthoma cells), which were
significantly larger in size than adjacent cells. We would
suggest that the increased size of lipid-laden macrophages
is potentially due to both intracellular uptake of lipids to-
gether with intralysosomal accumulation of P-407, which
is similar to what we have previously reported with Triton
WR-1339-filled lysosomes of liver cells [28]. Lastly, our
microscopic analysis revealed that a majority of hepato-
cytes were stained with Sudan III, which suggests that
protein-bound lipids were present. Since numerous
necrotic hepatocytes and intrahepatic cholestasis were also
noted in P-407-treated mice, the increase in serum
ALT and AST activity we detected would certainly
strengthen or support our qualitative microscopic
findings with liver cells.
As mentioned above, an increased level of circulating
serum lipoproteins and their uptake by liver was
followed by lipidosis as a result of intracellular lipid
storage. The natural question that arises from such a
finding is the identity of the cell compartment(s) in
which the lipids accumulate, i.e., inside of lysosomes or
outside of lysosomes [29]. In the present work, we have
acquired data which would support the involvement of
lysosomes in this process, although based on our results
with lipid staining using Sudan III, we cannot exclude the
possibility of extralysosomal lipid storage. Our measure-
ments of the free activity of lysosomal β-galactosidase
suggests an inability of the substrate (4-methylumbelliferyl
β-D-galactopyranoside) to reach the lysosomal enzyme
until the organelles are deliberately ruptured. Both an
increase in the free activity of β-galactosidase and
osmotically-induced lysosomal membrane rupture reflect
labilization of lysosomal membranes in P-407-treated
mice, which we would suggest is related to overloading of
lysosomes with lipids [30]. It should be pointed out that
the changes in lysosomal membranes in the liver cells of
P-407-treated mice may potentially reflect an increase in
autophagy (autophagocytosis) of liver cells [31] however,
further testing is required to confirm this premise.
Following one month of P-407 administration to mice,
we demonstrated an increase in cathepsin B activity in
heart tissue 24 h after the last dose of P-407, which
seemed to be positively correlated with the morphological
changes we observed in contractile-type cardiomyocytes
using light microscopy. As suggested by Chen et al. [32],
lysosomal membrane permeabilization and subsequent
release of lysosomal cathepsin B may contribute to the
development of coronary arteritis by activating the endo-
thelial Nlrp3 inflammasome. Moreover, cathepsins regulate
chemokine activity and play a role in leukocyte recruitment
during protective or pathological inflammation [33].
The rise in heart cathepsin B activity in P-407-treated
mice appears to signal the onset of cardiac tissue injury,
because atheroma formation normally commences at
approximately 1 month after initiating P-407 treatment
in this mouse model of atherogenesis [6]. In fact, it has
previously been reported that both the number and size
of atherosclerotic lesions formed in this animal model
typically attains a maximum at 4 months after beginning
P-407 administration [6]. It should also be noted that we
have reported a much greater increase in the activity of
cathepsin B in heart tissue when mice are treated with
P-407 for 4 months [5] when compared to the increase
in cathepsin B activity following 1 month of P-407 treat-
ment as used in the present study. Thus, this would
indicate that the magnitude of the elevation in heart ca-
thepsin B activity is positively correlated with the extent,
or degree, of heart injury as a function of time; i.e., the
net increase in heart cathepsin B activity and, therefore,
resulting cardiac tissue injury, is dependent on the
length of time that mice are treated with P-407 and
subjected to the resulting atherogenic, inflammatory
serum lipid profile, since P-407, by itself, is non-toxic to
most cells (including cardiomyocytes) at concentrations
utilized in the present study.
Conclusion
In this investigation, we used an experimental animal
model in which relatively small doses of P-407 were
repeatedly administered to mice for 1 month to achieve
a sustained, atherogenic serum lipid profile; specifically,
an increase in serum total TG, as well as atherogenic
LDL-cholesterol. The P-407-mediated increase in the
atherogenic LP-C fraction (LDL1–3-C subfraction) and
LP-TG (LDL1–3-TG subfraction) in serum was followed
by a return to normal values by day 4 following discon-
tinuation of P-407 treatment for 1 month. Significant
liver lipidosis was shown during all periods studied, with
lipid sequestration occurring primarily in liver cells
(macrophages and hepatocytes). It is suggested that
lipids (and possibly P-407) accumulate inside of lysosomes
based on an increase in lysosomal membrane permeabil-
ity, although both extralysosomal lipid storage and in-
creased autophagy cannot be unequivocally excluded.
Heart injury was characterized by morphological changes
in cardiomyocytes, as well as an increase in cathepsin B
activity. In summary, all of the cellular, biochemical and
pathophysiological changes (including an increase in
blood pressure) noted in the present study using P-407-
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treated mice are related to the symptoms of early athero-
sclerosis. Therefore, the P-407-induced mouse model of
hyperlipidemia and atherosclerosis might prove beneficial
as an experimental animal model with which to evaluate
the pathological changes that occur in humans during the
early stages of atherosclerosis. Importantly, this model
may potentially allow for the evaluation of new therapeu-
tics aimed at reversing or halting early-stage atheroma for-
mation in humans. These results are extremely relevant to
human health, since early medical intervention improves
patient outcomes (quality of life, lifespan, etc.) and reduces
the overall cost of health care for cardiovascular disease;
the number one cause of mortality in Western countries.
Methods
Male CBA mice having a body mass of 25–30 g were used
and obtained from the breeding station of the Institute of
Physiology, Siberian Branch of the Russian Academy of
Sciences, Novosibirsk, Russia. Poloxamer 407 (P-407)
(Pluronic F-127, Sigma) was administered to mice as an
intraperitoneal (i.p.) injection at a dose of 300 mg/kg twice
per week for one month [6]. The mice were decapitated at
1, 4 and 10 days after the last dose of P-407. Control mice
received an equivalent volume (0.5 mL) of saline. Mice
were deprived of food, but had free access to water, 15 h
before euthanasia. All procedures for agent administration
and blood and tissue collection were in accordance with
the 8th edition of the Guide for the Care and Use of
Laboratory Animals published in 2011 by the United
States National Academy of Sciences, and the treatment
protocol (animal protocol #9) was also approved by the
Animal Care and Use Committee at the Institute of Physi-
ology and Fundamental Medicine of the Siberian Branch
of the Russian Academy of Medical Sciences (RAMS) on
May 27, 2014. The in vivo experiments were also
conducted in compliance with RAMS Ethical Committee
Recommendations pertaining to research involving
laboratory animals.
The systolic and diastolic blood pressure was measured
in mice with a multi-channel, computerized non-invasive
blood pressure system for mice and rats (CODA, Kent
Scientific Corporation, Torrington, CT, USA) as described
previously [5].
Serum measurements of lipoprotein fractions and
subfractions
Serum was obtained after centrifugation of blood samples
at 3000 × g for 20 min at 4 °C (Eppendorf Centrifuge
5415R, Germany) and stored at −70 °C until analysis of
lipoprotein fractions and subfractions associated with
cholesterol (C), triglycerides (TG) and phospholipids (PL)
using small-angle X-ray scattering (SAXS). According to
Otvos [16], LP fractions can be divided into the following
four main classes: high density LP (HDL), low-density LP
(LDL), very-low-density LP (VLDL) and chylomicrons, or
seven subfractions: HDL3, HDL2, LDL, intermediate-
density LP (IDL), VLDL3–5, VLDL1–2 and chylomicrons
(chylomicrons were not determined by the method used).
Interval borders of fractions and subfractions (according
to the scale of sizes, ro) were the same as previously de-
scribed by Otvos [16]. The SAXS method for the deter-
mination of the fractional and subfractional composition
of LPs has been used and validated previously [17]. This
method is inexpensive, rapid and capable of determining
the relative content of different LP fractions, both as a size
distribution of various LP particles and as absolute units
of the total concentration of lipid in LP fractions. The
total LP-PL fraction was calculated by subtracting the sum
of LP-C + LP-TG from the total LP concentration. Using a
small sample of serum (0.1–0.25 ml), it was possible to
simultaneously assay the fractions and subfractions
associated with LP-C and LP-TG, and then readily
compute LP-PL. Lastly, while not lipids, we also
analyzed the serum for total protein, glucose and the
activity of ALT and AST using a biochemical analyzer
(Architect С8000; Abbott, USA).
Relationship of “SAXS-determined” lipoprotein fractions
and subfractions to atherogenicity
As stated above, SAXS was utilized to determine the
concentration of six lipoprotein fractions and subfractions
associated with cholesterol, triglycerides and phospho-
lipids; namely, VLDL1–2, VLDL3–5, IDL, LDL1–3, HDL2
and HDL3, however, the seventh lipoprotein fraction (chy-
lomicrons = CM) was not measured in the present study.
It is important to point out that our method (SAXS) quan-
tifies 7 lipoprotein fractions and subfractions, but, as an
example of the complexity involved with standardizing so
many lipoprotein fractions and subfractions identified
using a variety of analytical techniques, it has been
demonstrated that as many as 2 to 38 subfractions can be
separated and quantified for LDL alone [34].
Within the ‘SAXS-determined’ VLDL fraction, there
are 5 subfractions, with subfractions 1 and 2 (i.e., VLDL1
and VLDL2) representing small VLDL. VLDL1 and
VLDL2 are atherogenic due to their small size, apolipopro-
tein C-III content and enriched cholesteryl ester content.
Subfractions 3 and 4 represent intermediate/medium size
VLDL particles, which are less atherogenic than smaller
VLDL1 and VLDL2, but still able to enter arterial intima
and contribute to eventual atheroma formation. Finally,
subfraction 5 represents triglyceride-rich, larger VLDL
particles, which, like CM, are too large to potentially enter
the arterial wall. Within the LDL fraction, there are 3
subfractions. Subfractions LDL1 and LDL2 are highly
atherogenic due to their small size, increased density, abil-
ity to migrate across vascular endothelium, apolipoprotein
B-100 content, and, in approximately 10-20 % of serum
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LDL particles, apolipoprotein C-III content. Subfraction
LDL3 is a larger and less dense LDL particle than LDL1
and LDL2, and, therefore, slightly less atherogenic than
small, dense LDL subfractions LDL1 and LDL2.
The HDL fraction actually contains three subfractions
when analyzed by the SAXS technique and consists of
small dense and intermediate/medium size lipoprotein
particles. HDL1 and HDL2 subfractions represent the
small, dense HDL subfractions and HDL3 represents the
intermediate/medium size HDL subfraction. The HDL1
subfraction is not shown in our results (Fig. 2a, b and c),
because human and mouse serum typically contains only
a trace amount of HDL1 [35]. The HDL2 subfraction
contains apolipoprotein A-II and is therefore antiathero-
genic and confers the greatest protection against devel-
oping coronary artery disease, while subfraction HDL3,
being an intermediate/medium-sized HDL particle, is
generally less protective towards atherogenesis than
subfraction HDL2.
Lastly, IDL was historically a member of the LDL frac-
tion, but has been reclassified by itself due to its promin-
ent role in atherosclerosis. Because IDL contains both
apolipoprotein C-III and is rich in cholesteryl esters, it
represents a highly-atherogenic lipoprotein particle [15].
While the P-407-induced mouse model is already a
well-documented mouse model of atherogenesis, never-
theless, we also calculated a value known as the choles-
terol atherogenic coefficient (Kch) in the present study
[36]. Briefly, the Kch is defined as (VLDL-C + LDL-C)/
HDL-C and serves as a predictor of myocardial ischemia
[36]. The higher the value of Kch, the higher the risk of
atherogenic changes and the development of atheroscler-
osis. The mean values of VLDL-C, LDL-C and HDL-C
(Fig. 2a) for both control mice and P-407-treated mice
(24 h after stopping P-407 administration) were used to
calculate a representative Kch.
Membrane stability and osmotic sensitivity of lysosomes
In general, methods described by Wang et al. [37] and
Deng et al. [38] were used. Lysosomal stability (as reflected
by the degree of lysosomal membrane permeability when
measuring the release of the lysosomal enzyme, β-
galactosidase) was determined, as well as lysosomal mem-
brane susceptibility to hypoosmotic treatments (0.083 M
and 0.125 M sucrose solutions) in vitro. Additionally, lyso-
somal enzyme latency was assessed by measuring the free
activity associated with lysosomal β-galactosidase. The en-
zymatic activity of β-galactosidase was determined using a
fluorogenic method against 4-methylumbelliferyl N-acetyl-
β-D-galactosaminidepyranoside (Melford Laboratories,
England) as the substrate (1 mM, pH 5) [39]. Briefly, 2 %
liver homogenate solutions prepared in isotonic 0.25 M su-
crose with 1 mM Na-EDTA, pH 7.4, were diluted 10 times
by a 0.25 M sucrose solution and kept on ice or mixed with
cold distilled water in a 1:1 ratio (with immediate mixing)
and stored 30 min at 0 °C. The reaction was stopped by
the addition of 2 mL of Na-glycine buffer (pH 10.5).
Aliquots of the samples (50 μl) were then used for
the determination of free β-galactosidase activity. The
total activity of β-galactosidase was determined under
the same conditions using Triton X-100 (the final
concentration of Triton X-100 = 0.1 %). Fluorescence
was quantified on a Shimadzu RF-5301 PC spectroflu-
orimeter with an excitation wavelength of 360 nm
and an emission wavelength of 460 nm, using 4-
methylumbelliferon as the standard. The results were
expressed as the percent of the total activity.
Cysteine protease activity assay
Cysteine protease cathepsin B (EC 3.4.22.1) specific ac-
tivity was measured in heart and liver tissue according
to Barrett and Kirschke [40] using corresponding fluoro-
genic substrates Arg-Arg-MCA and Arg-Phe-MCA, re-
spectively, (Sigma, USA) (MCA =methylcoumarylamide)
at pH 6.0 (0.2 M phosphate buffer) for cathepsin B as
previously reported [5]. Incubation was performed in the
presence of 0.1 % Triton X-100 to destroy the cellular
membranes. The reaction was stopped by adding 0.1 M
monochloracetic acid. Fluorescence measurements were
recorded on a Shimadzu RF-5301 PC spectrofluorometer
using excitation and emission wavelengths of 355 nm
and 460 nm, respectively. MCA served as the standard.
The results were expressed as μmol of MCA cleaved per
min per g of protein. In the cathepsin L assay, a specific
inhibitor of cathepsin B (CA-074, 0.3 μM) was added to
the incubation medium to exclude the activity of cathep-
sin B.
Morphological evaluation of liver and heart tissue
For morphological analysis of liver and heart tissue,
samples were fixed with 10 % neutral-buffered formalin
and prepared using a MICROM HM 340E rotational
microtome (Carl Zeiss, Germany). Specimens were em-
bedded in histoplast and 4-μm cross-sections of tissues
were stained with hematoxylin and eosin according to
commonly-accepted procedures. The slices were evalu-
ated using light microscopy with an Axioscop 40 micro-
scope (Carl Zeiss, Germany). To more completely
evaluate lipid storage in liver, specimens were dehy-
drated and embedded in polyethylene glycol-1500 and
the sections subsequently stained with Sudan III and
hematoxylin.
Statistical analysis
All values were reported as the mean ± the standard
deviation (SD). Mean values of lipoprotein fractions and
subfractions within the various groups (LP-C, LP-TG
and LP-PL) were analyzed for statistically significant
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differences with the software program STATISTICA 10.0
using a one-way, analysis-of-variance (ANOVA). Post-hoc
analysis of ANOVA testing was performed using the Least
Significant Difference (LSD) test. When comparing only two
mean values, we used the Student’s t-test to identify a differ-
ence that was statistically significant. All statistical results
using either ANOVA, or the Student’s t-test, in which p <
0.05 were deemed statistically significantly different and were
noted in figures and tables. Correlation analysis was per-
formed using the Spearman test [41].
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